Page 11 - சுயாதீனமான தகவல்கள் கண்காணிப்பு குழு News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Company will stop exploring avdoralimab in COVID-19 Investigator-sponsored avdoralimab clinical trial in inflammation will continue MARSEILLE, France, July 06, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“ Innate” or the “ FOR COVID-19  Elimination), the investigator-sponsored, Phase 2 clinical trial evaluating the safety and efficacy of its anti-C5aR1 antibody, avdoralimab, in COVID-19 patients with severe pneumonia, did not meet its primary endpoints in all three cohorts of the trial. The FORCE trial was initiated based on pre-clinical data showing that patients who progress towards severe COVID-19 disease exhibit an activation of the C5a/C5aR1 pathway. These translational data were observed in the trial; however, they did not translate into clinical benefit over best supportive care.

Henry wheelerJulien carvelliJoyson karakunnelBristol myers squibbNovo nordiskCompany annual report on formFrench financial markets authorityExchange commissionData monitoring committeeEuronext parisChief medical officerLassistance publiqueTimone hospitalIndependent data monitoring committeeAcute respiratory disease syndromeInnate pharma